Partnerships 使用设备技术 and TRM Korea will strengthen Symani® Surgical System’s entrance into the world’s fastest-growing surgical robotics market.
MMI, (Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that it will continue its global momentum with two distribution agreements covering nearly a dozen countries in the Asia Pacific (APAC) region. 第一次合作, 使用设备技术, will help to introduce the Symani Surgical System to Hong Kong, 新加坡, 越南, 马来西亚, 印尼, 泰国, 菲律宾, 澳门, 和新西兰, upon applicable regulatory approvals, 以及澳大利亚, where it recently received approval from the Therapeutic Goods Administration (TGA). 另一个伙伴关系, 与韩国TRM合作, will facilitate the system’s entry into South Korea upon regulatory approval and will introduce microsurgical robotic technology to interested surgeons and hospitals.
The Symani Surgical System is a first-of-its-kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can expand treatment options for patients in need of soft tissue open surgical procedures, such as free flap reconstructions, 淋巴手术, 以及创伤重建. It is designed to help restore quality of life for more patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.
“Through our new partnerships in Asia Pacific, we have established roots that will ultimately help us expand patient access to robotic microsurgical and supermicrosurgical capability in a region of the world with clear demand for the technology,” said Matt Lemay, VP of Asia Pacific of MMI. “Surgeons from the APAC region have long been at the forefront of innovation in microsurgery, and we look forward to helping further those capabilities with the Symani Surgical System. As we advance our mission of increasing treatment options for patients with complex conditions, we are enthusiastic about our global progress and look forward to continuing our momentum in APAC and beyond.”
Device Technologies has provided healthcare professionals access to innovative, 高品质医疗器械, including leading robotics solutions, 30多年来. They will open a new research and education center for robotic microsurgery with a premier medical institution as part of their partnership with MMI. The center will represent the first site in Central Asia where interested surgeons can learn more about the system.
“MMI and the Symani Surgical System are well aligned with our core mission to provide physicians and healthcare facilities with solutions that can drive improved patient outcomes,” said Heath Priestly, Managing Director at Device Technologies. 原产于澳大利亚, we have broadened our presence throughout the Asia Pacific region, establishing expertise and strong connections. We are eager to use our footprint to support MMI’s health system partnerships across the region and further increase patient access to sophisticated surgical techniques for complex conditions.”
TRM is the largest microsurgery company in South Korea and a pioneer in the medical technology and innovation space. They are collaborating with a world-renowned medical institution to open their own education center where surgeons will have the opportunity for informational sessions and hands-on learning about the Symani Surgical System. 要了解更多关于MMI的信息，请访问 http://mmimicro.com.
关于MMI
MMI (Medical Microinstruments, Inc.) is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, 意大利, and its proprietary Symani® Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair, 淋巴修复, 周围神经修复. The Symani System is CE Marked for commercial use in Europe. In the United States, the system is not approved or cleared for commercial use. MMI is backed by international medtech investors including Andera Partners, BioStar, 迪尔菲尔德中学管理, bet亚洲365欢迎投注, Panakes伙伴, RA的资本, Sambatech, 惠灵顿合作伙伴.